Nanomaterials modulating TAMs polarization for the treatment of pancreatic cancer
Nanomaterials modulating TAMs polarization for the treatment of pancreatic cancer.(A) The NF-κB and HIF-1αsignaling pathway. (1) TAMs phagocytose nab-paclitaxel. Nab-paclitaxel promotes TLR4, activates the NF-κB signaling pathway, and induces M2-type TAM polarization to M1-type. (2) ppp dsRNA LCP-AEAA NPs knock out Bcl2 in pancreatic cancer cells and induce apoptosis. In addition, ppp dsRNA activates RIG-I, induces M2-type TAM polarization to M1-type, and releases TNF-α. The NF-κB signaling pathway may be involved. (3) Oxygen microcapsules release the oxygen, which inhibit the HIF-1αsignaling pathway and the polarization of M2 type TAM.(B) The PI3K/AKT signaling pathway. (1) GD@PP/Wtmn decomposed into GD and PP/Wtmn via CTSB in the pancreatic tumor tissue. GD induces apoptosis in pancreatic cancer cells. Wtmn in PP/Wtmn mice inhibited PI3K and subsequently AKT in M2-type TAMs, impairing TAM polarization to M2-type TAMs. (2) M2pep-MM/BEZ/siRNA targets M2-type TAMs to release BEZ 235 and CSF-1RsiRNA. BEZ 235 inhibited the PI3K/AKT signaling pathway in M2-type TAMs and weakened M2-type TAM polarization. CSF–1R knockdown using CSF–1R siRNA attenuates M2-type TAM polarization.(C) MicroRNAs: miR-155 and miR-125b. (1) HA-PEI/HA-PEG nanoparticles-encapsulated miR-155 and miR-125b were phagocytosed by pancreatic cancer cells to produce exosomes containing miR-155 and miR-125b. After being engulfed by M2-type TAMs, they promote M2-type TAM polarization to M1-type. (2) The HA-PEl/PEG-M2 peptide miR-125b targets M2 type TAMs through M2pep, and miR-125b promotes M2-type TAM repolarization to M1-type.(D) CB-2. siMGLL/siCB-2 high GSH concentration in the cytoplasm promoted the release of siMGLL and siCB-2. siMGLL inhibited MGLL expression in pancreatic cancer cells, thereby inhibiting FFAs. siCB-2 inhibits CB-2 expression in M2-type TAMs, thereby promoting M2-type TAM polarization to M1-type and inhibits pancreatic cancer cells. TAMs, Tumor-associated macrophages; NF-kB, Nuclear factor-kappaB; HIF-1α, Hypoxia-inducible factor-1α; Nab-paclitaxel, Nanoparticle albumin-bound paclitaxel; TLR4, Toll-like receptor 4; ppp dsRNA LCP-AEAA NPs, 5′ triphosphate double-stranded RNA Lipid calcium phosphate-targeted with aminoethyl anisamide nanoparticles; Bcl2, B-cell lymphoma 2; ppp dsRNA, 5′ triphosphate double-stranded RNA; RIG-I, Retinoic acid-inducible gene I; TNF-α, Tumor necrosis factor-α; PI3K, Phosphatidylinositol-3hydroxykinase; AKT, AGC serine/threonine kinases; GD@PP/Wtmn, GEM conjugated dendritic poly-lysine DGL encapsulated to polycaprolactone-polyethylene glycol micelles loaded with wortmannin; CTSB, Cathepsin B; GD, GEM conjugated dendritic poly-lysine DGL; PP/Wtmn, polycaprolactone-polyethylene glycol micelles loaded with wortmannin; Wtmn, Wortmannin; M2pep-MM/BEZ/siRNA, M2 macrophage-binding peptide- Mixed micelle/BEZ 235/short interfering RNA; HA-PEI/HA-PEG NP-Encapsulated miR-155 and miR-125b, Hyaluronic acid-poly (ethylene imine)/hyaluronic acid-poly (ethylene glycol) Nanoparticles-Encapsulated miR-155 and miR-125b; M2pep, M2 macrophage-binding peptide; CSF-1RsiRNA, Colony stimulating factor-1 receptor siRNA; CSF–1R, Colony stimulating factor-1 receptor; HAPEI/PEG-M2peptide miR-125b NPs, Hyaluronic acid-poly (ethylene imine)/hyaluronic acid-poly (ethylene glycol)- M2peptide miR-125b Nanoparticles; CB-2, Endocannabinoid receptor-2; NPs(siMGLL/siCB-2), NPs for co-delivery of MGLL siRNA and CB-2 siRNA; GSH, Glutathione; FFAs, Free fatty acids